Drug intelligence / Profile preview

RBF4

Development stage: Unknown
Lead developer: Virginia Commonwealth University

Overview

RBF4: sourced facts only. name: "Thermal shift assays revealed that RBF4 preferentially stabilizes USP11 compared to other functional paralogues USP4 and USP15, which validates the selective USP11-RBF4 interaction." [DOI:10.1158/1538-7445.am2023-lb023]; target: "Thermal shift assays revealed that RBF4 preferentially stabilizes USP11 compared to other functional paralogues USP4 and USP15, which validates the selective USP11-RBF4 interaction." [DOI:10.1158/1538-7445.am2023-lb023]; developer: "1Virginia Commonwealth University, Richmond, VA." [DOI:10.1158/1538-7445.am2023-lb023]

Targets

USP11 (Ubiquitin specific peptidase 11)

Beyond the preview

Go deeper on RBF4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBF4.